platinum has been researched along with bortezomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A | 1 |
| Cheng, Y; Wang, C; Wang, X; Zhang, Q | 1 |
1 trial(s) available for platinum and bortezomib
| Article | Year |
|---|---|
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
1 other study(ies) available for platinum and bortezomib
| Article | Year |
|---|---|
Near infrared light-responsive and injectable supramolecular hydrogels for on-demand drug delivery.
Topics: alpha-Cyclodextrins; Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Survival; Dendrimers; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Fever; Humans; Hydrogels; Infrared Rays; Macromolecular Substances; Metal Nanoparticles; Mice; NIH 3T3 Cells; Platinum; Polyethylene Glycols; Structure-Activity Relationship | 2016 |